Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Galena Biopharma Inc (NASDAQ:GALE)

0.4661
Delayed Data
As of 4:00pm ET
 +0.1161 / +33.17%
Today’s Change
0.28
Today|||52-Week Range
2.49
-68.29%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$63.6M

Company Description

Galena Biopharma, Inc. engages as a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. It focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral (fentanyl) sublingual tablets and Zuplenz (ondansetron) oral soluble film. The company was founded by Craig Mello on April 3, 2006 and is headquartered in San Ramon, CA.

Contact Information

Galena Biopharma, Inc.
2000 Crow Canyon Place
San Ramon California 94583
P:(925) 498-7700
Investor Relations:
(503) 405-8258

Employees

Shareholders

Mutual fund holders8.83%
Other institutional6.78%
Individual stakeholders0.41%

Top Executives

Mark W. SchwartzPresident, Chief Executive Officer & Director
Gavin S. ChoySenior VP-Clinical Sciences & Operations
Bijan NejadnikChief Medical Officer & Executive Vice President
Patricia A. MurphyVice President-Regulatory & Compliance
Joseph LasagaVP-Business Development & Alliance Management